Evan David Seigerman
Stock Analyst at BMO Capital
(2.67)
# 2,028
Out of 4,876 analysts
44
Total ratings
32.5%
Success rate
1.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $16.57 | +56.91% | 2 | Jun 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $800 → $600 | $521.00 | +15.16% | 7 | Jun 2, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $53.18 | +106.84% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.21 | +26.07% | 1 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $7.80 | +28.21% | 1 | May 5, 2025 | |
| NVO Novo Nordisk | Downgrades: Market Perform | $105 → $64 | $67.70 | -5.47% | 6 | Apr 17, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $78.83 | +21.78% | 4 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $208 → $215 | $186.79 | +15.10% | 7 | Feb 3, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $279.11 | +23.97% | 4 | Jan 29, 2025 | |
| REPL Replimune Group | Maintains: Outperform | $18 → $27 | $9.46 | +185.41% | 3 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $21.08 | +374.38% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.24 | +48.51% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.03 | -40.36% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $795.12 | -50.20% | 1 | Sep 6, 2022 |
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $16.57
Upside: +56.91%
Regeneron Pharmaceuticals
Jun 2, 2025
Maintains: Outperform
Price Target: $800 → $600
Current: $521.00
Upside: +15.16%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $53.18
Upside: +106.84%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.21
Upside: +26.07%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $7.80
Upside: +28.21%
Novo Nordisk
Apr 17, 2025
Downgrades: Market Perform
Price Target: $105 → $64
Current: $67.70
Upside: -5.47%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $78.83
Upside: +21.78%
AbbVie
Feb 3, 2025
Maintains: Outperform
Price Target: $208 → $215
Current: $186.79
Upside: +15.10%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $279.11
Upside: +23.97%
Replimune Group
Jan 22, 2025
Maintains: Outperform
Price Target: $18 → $27
Current: $9.46
Upside: +185.41%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $21.08
Upside: +374.38%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.24
Upside: +48.51%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.03
Upside: -40.36%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $795.12
Upside: -50.20%